JCI Insight · 2018 · 117 citations · 35 references
Life SciencesImmunologyMolecular MedicineImmunoregulationInnate ImmunityMolecular ImmunologyInnate Immune ActivationInnate Immune RecognitionInnate Immune ResponseInnate Immune Signaling PathwaysInterferon ResponsesToll-like ReceptorsAdeno-associated Viral VectorsCoagulation Factor ActivationDouble-stranded Rna SensingImmune Responses To Gene Delivery VectorsInnate Immunity PathwaysMda5 SignalingRetroviral Vector TransductionVector Transduction
Data from clinical trials for hemophilia B using adeno-associated virus (AAV) vectors have demonstrated decreased transgenic coagulation factor IX (hFIX) expression 6-10 weeks after administration of a high vector dose. While it is likely that capsid-specific cytotoxic T lymphocytes eliminate vector-transduced hepatocytes, thereby resulting in decreased hFIX, this observation is not intuitively consistent with restored hFIX levels following prednisone application. Although the innate immune response is immediately activated following AAV vector infection via TLR pathways, no studies exist regarding the role of the innate immune response at later time points after AAV vector transduction. Herein, activation of the innate immune response in cell lines, primary human hepatocytes, and hepatocytes in a human chimeric mouse model was observed at later time points following AAV vector transduction. Mechanistic analysis demonstrated that the double-stranded RNA (dsRNA) sensor MDA5 was necessary for innate immune response activation and that transient knockdown of MDA5, or MAVS, decreased IFN-β expression while increasing transgene production in AAV-transduced cells. These results both highlight the role of the dsRNA-triggered innate immune response in therapeutic transgene expression at later time points following AAV transduction and facilitate the execution of effective strategies to block the dsRNA innate immune response in future clinical trials.
35
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses
Hiroki Kato, Osamu Takeuchi, Shintaro Sato et al. · Nature · 2006 · 3.8K citations
IL-28, IL-29 and their class II cytokine receptor IL-28R
Paul O. Sheppard, Wayne Kindsvogel, Wenfeng Xu et al. · Nature Immunology · 2002 · 1.6K citations
Hiroki Kato, Osamu Takeuchi, Eriko Mikamo-Satoh et al. · The Journal of Experimental Medicine · 2008 · 1.6K citations · Full text